×

References: 1. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Redwood City, CA. 2. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410 3. Janni W, Huober J, Braun T, et al. Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence. Poster presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; Philadelphia, PA. Accessed November 1, 2022. https://doi.org/10.1158/1538-7445.AM2022-3403 4. Nagasaka M, Uddin MH,
Al-Hallak MN, et al. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82. doi:10.1186/s12943-021-01371-1 5. Larribère L, Martens UM. Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors. Cancers (Basel). 2021;13(22):5698. doi:10.3390/cancers13225698

The only tissue-free MRD test for colorectal, breast, and lung cancers.1-5

Important Note: The Guardant Reveal test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal refers to Guardant Reveal Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA. 

×

Reference: 1. GuardantINFINITY™: Specifications Sheet. Guardant Health, Inc. Redwood City, CA. January 4, 2023.

The market-leading liquid CGP that identifies actionable biomarkers.1,2

The new liquid biopsy assay that combines the power of genomic and epigenomic profiling.1

×

References: 1. Brand Tracker: 4Q22. Guardant Health, Inc. Redwood City, CA. December 2022. 2. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021.

For research use only. Not for use in diagnostic procedures.

×

Reference: 1. GuardantINFINITY™: Specifications Sheet. Guardant Health, Inc. Redwood City, CA. January 4, 2023.

The platform that provides epigenomic insights from our cutting-edge methylation technology.1